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Background: Recently, involvement of the chemokine/receptor system CCL20/CCR6 in colorectal cancer (CRC)
progression was shown. Here, we analyzed the functional interaction of miRNA-518-5p (miR-518a-5p) with CCR6
and its impact on CCR6 expression in CRC cells.
Methods: MiR-518a-5p was identified by computer software to potentially interact with CCR6. Hence, functional
implications of miR-518a-5p with the 3′UTR of CCR6 were analyzed using the Dual Luciferase Reporter assay system.
Confirmation of the predicted target site for miR-518a-5p was achieved by site-directed mutagenesis of the seed
sequence in the 3′UTR of CCR6 and subsequent application of the mutated seed sequence in a luciferase assay
with miR-518a-5p mimics. Accordingly, two CRC cell lines (Caco-2 and HT-29) were transfected with miR-518a-5p
miRNA mimics and gene and protein expression of CCR6 was monitored using qRT PCR and immunocytochemistry,
respectively.
Results: Addition of miR-518a-5p led to significant down-regulation of luciferase activity (P < 0.05), which was
significantly reversed in a reporter test system containing the mutated seed sequences in the 3′UTR of CCR6.
Following transfection of CRC cell lines with miR-518a-5p mimics and subsequent monitoring of CCR6 expression
showed significant down-regulation of CCR6 mRNA and CCR6 protein expression in both CRC cell lines under
investigation (P < 0.05).
Conclusions: We have shown that miR-518a-5p functionally interacts with CCR6 and that transfection of CRC
cells with miR-518a-5p leads to significant CCR6 down-regulation. Consequently, CCR6 expression is regulated by
miR-518a-5p in CRC cells indicating that regulation of CCR6 expression by miR-518a-5p might be a regulatory
mechanism involved in CRC pathogenesis.
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MicroRNAs (miRNAs) are recently studied evolutionarily
conserved, naturally occurring non-coding RNAs which
are characterized by their short size (19–25 nucleotides),
lack of a poly-A tail and their ability to bind cognate
mRNA targets with sequence homology [1,2]. As key con-
trol elements of crucial regulatory pathways in plants and
animals miRNAs were shown to regulate gene expression
post-transcriptionally by binding to the 3′ untranslated re-
gions (UTRs) of target mRNAs, thereby inhibiting mRNA
translation [3,4].* Correspondence: claudia.rubie@uks.eu
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reproduction in any medium, provided the orTo date, miRNAs are known to play a role in a wide
range of cellular processes and although a few thousand
predicted miRNAs have been identified in a variety of
organisms, little is known about their cellular functions. It
is estimated that as high as 30% of protein-coding genes
could serve as miRNA targets. As miRNAs often regulate
multiple transcripts, they are involved in various biological
processes comprising cell differentiation, proliferation,
apoptosis, metabolism, protein secretion and host-patho-
gen interactions including viral infection. While several
studies have recently described aberrant expression of
miRNAs in different cancer entities, it is yet unknown if
this directly influences the carcinogenic process [5,6].
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inhibit the translation of proto-oncogenes in normal
tissues. In contrast, other miRNAs are referred to as “onco-
miRs” because their up-regulation leads to the down-
regulation of tumor suppressor genes. As both oncogenes
and tumor suppressor genes can be targets of dysregulated
miRNAs, the function of a special miRNA may depend
highly on the target and the cell environment [7].
In the last decade, also chemokines have been shown
to participate in tumor growth and angiogenesis and the
lymphatic and even distant spread of malignant tumors
[8-13]. The biological effects of chemokines are exerted
by interacting with seven-span transmembrane domain
receptors coupled to trimeric G proteins, that are select-
ively found on the surfaces of their target cells. Con-
sequently, chemokines and their receptors my facilitate
dissemination of tumor cells at each of the key steps of
metastasis like adhering to endothelium, extravasation
from blood vessels, angiogenesis, colonization, proliferation
and protection from the host response [14]. Moreover,
chemokines play an important role in the communication
between cancer cells and non-cancerous cells like endo-
thelial cells, neutrophils, fibroblasts and tumor-associated
macrophages in the tumor-microenvironment.
Recently, various cancer-related studies demonstrated
that specific chemokines and their receptors are dysreg-
ulated in CRC and may be involved in the molecular
mechanisms controlling CRC pathology. In this respect,
interactions between the inflammatory and homeostatic
chemokine CCL20 and its receptor CCR6 were shown
to be involved in CRC pathology [15,16]. In this context,
expression of CCL20/CCR6 was found to be significantly
up-regulated in CRC, where the CCL20/CCR6 system
was recently shown to be a critical component in the
regulation of CRC progression and spread which can
also be influenced by chemotherapy [17]. In addition,
CCL20 stimulation of CRC cells leads to phosphorylation
of an adaptor/scaffolding protein involved in adhesion and
migration as well as to increased cancer cell proliferation
and migration and the activation of the ERK-MAP kinase
and Act pathways [18,19]. The precise mechanisms under-
lying the regulation of CCL20/CCR6 involvement in CRC
remain still unclear. Recently, in CRC the expression of
various miRNAs has been demonstrated to be down-regu-
lated [20,21]. Based on the assumption that a down-regu-
lated miRNA may cause an increased expression of its
target chemokine, we recently investigated functional
interactions of several miRNAs with chemokine ligand
CCL20. Accordingly, we have outlined a functional inter-
action of miR-21 with the 3′UTR of CC– chemokine
ligand CCL20 [22]. However, investigating the cellular
localization of miR-21 and its target CCL20 revealed that
both molecules are expressed predominantly in the
microenvironment of CRC tumors [23]. In this study,we aimed to explore functional interactions between
potential miRNA candidates and CCL20 receptor CCR6.
After identifying miR-518a-5p to potentially interact with
CCR6 in a luciferase assay system, we investigated its




The miRNA target sites on the CCR6 (NM_004367.5) 3′
UTR were predicted using the following programs: Tar-
getScan Human 5.1, MicroRNA.org, MicroCosm Targets,
MiRDB and TargetMiner as presented with the corres-
ponding websites in Table 1.
Dual Luciferase Reporter assay
For the luciferase assays dual luciferase reporter vectors
were used which contained either the 3′UTR of CCR6 (Luc
CCR6 vector), a control with no 3′UTR (Luc No CCR6
vector; both Genecopoeia Inc; Rockville, MD, USA) or a
mutated 3′UTR of CCR6 (Luc CCR6 Mut vectors) as pre-
sented in Table 2. For the reporter assays 293 T cells were
cultured in a 24-well plate for 24 h. At a confluency of ap-
proximately 80% cells were cotransfected with Luciferase
CCR6 vector, Luciferase No CCR6 vector or Luciferase
CCR6 Mut vectors and the miR-518a-5p or negative con-
trol Pre-miR (NK) miRNA mimics for 48 hours using Li-
pofectamine 2000 (Life Technologies, Carlsbad, CA). The
activities of Firefly (Photinus pyralis) and Renilla (Renilla
reniformis) luciferase were quantified with the Dual lucif-
erase Reporter Assay System from Promega Corp (Madi-
son, WI, USA). For normalisation of transfection
differences Firefly luciferase activity was related to Renilla’s
counterpart. In general, luciferase activities of luciferase
CCR6 vector constructs were normalized to Luciferase No
CCR6 vector constructs. All values were normalized to
the negative control Pre-miR miRNA Precursors.
Site-directed mutagenesis
To determine whether the predicted target site for hsa-
miR-518a-5p is a functional target site we mutated the
Table 2 Luciferase assay vectors -overview
Vector Type Example
CCR6-3′UTR + luciferase gene (firefly) Dual luciferase reporter assay system
with unmutated regulatory region of CCR6
Luc CCR6 vector (GeneCopoeia) CatalogNo: HmiT002212-MT01
No 3′UTR + luciferase gene (firefly) Dual luciferase reporter assay without
regulatory region of CCR6
Luc No CCR6 vector (GeneCopoeia) CatalogNo: CmiT000001-MT01
Mutated CCR6-3′UTR + luciferase
gene (firefly)
Dual luciferase reporter assay with
mutated regulatory region of CCR6
Luc CCR6 Mut vectors Lab construction vectors CatalogNo:
HmiT002212-MT01 with point mutations in the miR-518a-5p
seed sequences
• Mutations in BS1 • Luc CCR6 Mut BS1
• Mutations in BS2 • Luc CCR6 Mut BS2
• Mutations in BS1 + 2 • Luc CCR6 Mut BS1 + 2
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mutated seed sequence in a subsequent luciferase assay.
The predicted target sequence 5′-CTTTGCA-3′ was
mutated to 5′-TAGACTC-3′ in seed sequence 1 and 2
of the 3′UTR of CCR6. Site-directed mutations were
generated by PCR using the HmiT002212-MT01 repor-
ter vector (GeneCopeia) as a template and the QuikChange
II XL site-directed mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer’s instructions. In the
first step of the mutagenesis process we mutated the first
seed sequence (position 222–228) by introducing four
point mutations into the CCR6 3′UTR of Luciferase re-
porter vector HmiT002212-MT01 resulting in the respect-
ive mutated vector Luc CCR6 Mut BS1. Likewise, we
introduced the same four point mutations into the second
seed sequence of the 3′UTR of CCR6 (position 1773–
1779) resulting in the respective mutated vector Luc CCR6
Mut BS2. Subsequently, vector Luc CCR6 Mut BS1 was
applied as a template to introduce a site-directed mutagen-
esis into the second seed sequence of the 3′UTR of CCR6.
Thus, we have introduced the same four point mutations
into the second seed sequence of the 3′UTR of CCR6 of
vector Luc CCR6 Mut BS1 resulting in vector Luc CCR6




3′ and REVERSE: 5′-CCTAGAGCTACAAAACATTCC
TCTCAGATTGCTGGAAAATGCTACC TATCAGAG
AC-3′.
The primers used for site-directed mutagenesis of the
second seed sequence at position 1773–1779 were:
FORWARD: 5′-CAAAGTCTGTATTTTTAAAGCAT
GGCTTTGGGTCTGGGAAATAAA AAATGTGTTTT
GTACATGAAGTAG-3′ and REVERSE: 5′-CTACTTC
ATGTACAAAACACATTTTTTATTTCCCAGACCCA
AAGCCA TGCTTTAAAAATACAGACTTTG-3′.
The mutagenized plasmids were isolated using the
Qiagen Miniprep Kit (Qiagen). The mutations were
confirmed by DNA sequencing (Seq-it, Kaiserslautern,
Germany) of the region containing the mutation. Largescale plasmid isolations were performed using the GenE-
lute™ HP Plasmid Maxiprep Kit (Sigma Aldrich, Munich,
Germany). The modified plasmids were designated Luc
CCR6 Mut BS1, Luc CCR6 Mut BS2 and Luc CCR6 Mut
BS1 + 2, respectively, as presented in Table 2.
miRNA assays
miRNA transfection (miR-518a-5p) of HT-29 and Caco-
2, cells was performed according to the HiPerFect
Transfection Reagent Handbook from Qiagen (Qiagen,
Hilden, Germany) and the Dharmacon DharmaFECT
RNA transfection protocol (Thermo Fisher Scientific,
Waltham, USA). Briefly, cells were trypsinized, counted
and on average 5 × 105 cells per well of a 6-well plate,
were seeded and overnight incubated under their normal
growth conditions. Before transfection of Caco-2 cells 5
nM of miRNA mimics were diluted in 100 μl of DMEM
and 6 μl of Dharmafect were diluted in 94 μl of DMEM
and incubated for 5 min. Hence the two samples were
mixed and incubated for 20 min to allow formation of
transfection complexes. Subsequently the samples were
incubated for 10 min to allow formation of transfection
complexes. Accordingly, the complexes were added drop-
wise to the cells and incubated under their normal growth
conditions. Gene expression of CCR6 was monitored after
48 and 72 hours after transfection with miRNA miR-518a-
5p at the mRNA and at the protein level using qRT PCR
and immunocytochemistry, respectively. As a positive
control the expression of TWF1 upon transfection of
hsa-miR-1 was monitored. Further, control samples
with untransfected cells, a mock-transfection with only
transfection reagent and a negative control miRNA (NK)
were applied. A detailed overview of miRNA control ex-
periments is presented in Table 3.
Single-strand cDNA synthesis
Isolation of total RNA from cell lines was performed
using the Qiagen RNeasy Mini Kit according to manu-
facturer’s instructions. Integrity of RNA samples was con-
firmed spectrophotometrically and by electrophoresis on
1% agarose gels.
Table 3 miRNA assay control experiments - overview
Control experiment Type Example
Positive control miRNA miRNA that is known to downregulate its target gene miR-1 Mimic (targeting TWF1)
Negative control miRNA (NK) A nonsilencing miRNA with no homology to any known
mammalian gene
microRNA Mimic negative control
(Applied Biosystems)
Mock transfection control Control experiment where cells go through the transfection
process without addition of miRNA
Untransfected cells control Control experiment where gene expression analysis is carried
out on cells that have not gone through the transfection process
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sample was reverse-transcribed in a final reaction vol-
ume of 50 μl containing 1× TaqMan RT buffer, 2.5 μM
random hexamers, 500 μM each dNTP, 5.5 mM MgCl2,
0.4 U/μl RNase inhibitor, and 1.25 U/μl Multiscribe RT.
The cycler conditions were 10 min at 25°C, 90 min at
48°C, and 5 min at 95°C.
Quantitative real-time PCR
The q-RT-PCR for CCR6 mRNA detection was per-
formed using 10 μl 2× Taqman Universal PCR Master
Mix II and 1 μl CCR6 gene assay Applied Biosystems
Life Technolgies (Carlsbad, CA, USA), 8 μl RNAse-free
water and 1 μl cDNA template (20 ng/μl).
The theoretical basis of qRT assays is described in
detail elsewhere [24]. Triplicates were run for all reactions
together with no template controls and an additional con-
trol for DNA contamination where the reverse transcript-
ase was omitted. As detection system the ABI Prism 7900
sequence detector (Applied Biosystems Life Technologies)
was programmed to an initial step of 10 min at 95°C,
followed by 40 thermal cycles of 15 s at 95°C and 10 min
at 60°C and the log-linear phase of amplification was
monitored to obtain CT values for each RNA sample.
The expression level of CCR6 mRNA was analyzed in
relation to the levels of the slope matched housekeeping
gene Cyclophilin C (CycC) [25]. Conversion of the indi-
vidual CT values to the linear form was performed accord-
ing to the 2-delta CT method.
Isolation of total protein
Isolation of protein was performed using frozen tissue or
cells in 6-well plates and protein lysates became precipi-
tated by the use of RIPA buffer. Quantification of protein
in the samples was conducted using the Pierce BCA
Protein Assay Reagent Kit (Pierce, Rockford, IL, USA).
Immunocytochemistry
Immunocytochemical staining of CRC cells was perfor-
med using BD Falcon CultureSlides (BD Falcon Ref.:
354104, BD Biosciences Discovery Labware, Bedford, MA,
USA) comprised of a glass slide treated to provide a con-
sistent surface for cell growth and 4 compartmentalized
chambers molded from polystyrene. Cells of CRC celllines HT-29 and Caco-2 were seeded with a density of
1×105 cells per ml on the culture slides. After adhesion
cells were transfected with miR-518a-5p (5 μM) according
to the Dharmacon DharmaFECT RNA transfection pro-
tocol (Thermo Fisher Scientific, Waltham, USA). After an
incubation time of 72 hours at 37°C and 5% CO2 the
supernatant was removed and cells were washed with PBS
followed by a 10 min fixation in ice cold methanol. Hence,
the chambers were removed followed by sequential wash-
ing steps. After blocking of endogenous peroxidase activity
with 3% hydrogen peroxide, the sections were treated
with avidin and biotin (Avidin/Biotin blocking kit, Vector
Laboratories Inc., Burlingame, CA, USA). In addition un-
specific binding sites were further blocked for 30 min at
room temperature with normal rabbit serum.
Overnight incubation at 4°C with primary goat polyclonal
anti-human CRR6 antibody (diluted 1:125, C2099-70B,
Biomol, Hamburg, Germany) was followed by incubation
of secondary biotinylated rabbit anti-goat IgG antibody
and the avidin-biotin-peroxidase reaction (Vectastain ABC
ELITE Kit, Vector Laboratories, Burlingame, CA, USA).
After colour reaction with aminoethylcarbazol solution
(Merck, Darmstadt, Germany), cells were counterstained
with haematoxylin. Negative controls were conducted in
all cases omitting primary antibody. For evaluation of
immunocytochemical staining the total number of cells per
5 high-power fields (using x40 –HPF objective magnifica-
tion) was determined. Cells were considered positive, when
they demonstrated strong and exclusive labelling.
Cell culture and reagents
Human embryonic kidney (HEK) cell line 293 T was main-
tained in Dulbecco’s modified Eagle’s medium (Invitrogen
Life Technologies, Carlsbad, CA, USA). CRC cell line
HT29 was cultivated in McCoy’s + GlutaMAX medium
and CaCo2 cell line was maintained in MEM+GlutaMAX
Medium. The medium contained 10% (v/v) Fetal Bovine
Serum Gold (PAA Laboratories GmbH, Pasching, Austria)
and 1% (v/v) Penicillin/Streptomycin (Invitrogen Life Tech-
nologies). All cell lines were cultured in a 5% CO2-humidi-
fied incubator (Nalge Nunc International, Rochester, NY,
USA) at 37°C.
The Pre-miR miRNA Precursor of miR-518a-5p (Ambion
Life Technologies, Carlsbad, CA, USA; Cat. No. 17100 ID:
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nologies, Cat. Nr. 17110) were purchased from Ambion
Life Technologies.
Calculations and statistical methods
CCR6 and luciferase expression profiles of the different
groups are shown as mean and standard error of the
mean (SEM). Comparison of luciferase activities between
miR-518a-5p cotransfected groups with the luciferase
vector constructs Luc No CCR6, Luc CCR6 and Luc
CCR6 Mut1, 2 and 1 + 2 was performed with one way
analysis of variance (ANOVA) with the Bonferroni-Post-
hoc-Test. Where appropriate, the Student’s t-test was
applied to test for group differences of continuous vari-
ables. All calculations were done with SPSS, version 19.
The significance level was p < 0.05.
Results
Screening for microRNA target sites in the 3′UTR of CCR6
To identify miRNAs that potentially interact with the 3′
UTR of CCR6, various prediction software tools were
applied. Only miRNAs that were identified by two or
more out of the five queried target prediction programs
were selected for experimental investigations. For miR-
518a-5p, three of five target prediction programs under
investigation, TargetScan Human 5.1, MiRDB and Target-
Miner predicted a potential interaction with CCR6 as
presented in Table 1 and Figure 1. As shown in Figure 1
the predicted alignment sequences of miR-518a-5p
include positions 222–228 and 1773–1779 on the 3′UTR
of CCR6.
MicroRNA 518 functionally interacts with the 3′UTR of CCR6
Next, we examined whether miR-518a-5p potentially
influences the regulation of CCR6 gene expression. Func-
tional implications of miR-518a-5p with the 3′UTR of
CCR6 were analyzed using the Dual Luciferase ReporterFigure 1 Predicted miRNA target sites (PTSs) on the CCR6 3′UTR. Hsa-
Human 5.1, MiRDB and TargetMiner to align to positions 242–228 and 177
continuous lines.assay system. The luciferase reporter vectors contained
either a control vector with no 3′UTR (Luc No CCR6-
vector) or the 3′UTR of CCR6 downstream of the firefly
luciferase gene (Luc CCR6 vector) as demonstrated in
Figure 2A, B and C. Co-transfection of HEK cell line
293 T with the Luc CCR6 vector and miR-518a-5p pre-
cursors, respectively, resulted in a significant 60% down-
regulation of luciferase activity (P < 0.05) as presented in
Figure 3. Thus, miR-518a-5p regulates the expression of a
luciferase construct which contains the 3′UTR of CCR6.
Site-directed mutagenesis of the seed sequence verifies
functional interaction of miR-518a-5p with CCR6
A site-directed mutagenesis spanning 4 bp was intro-
duced into the two seed sequences of the 3′UTR of
CCR6, respectively, resulting in three modified plasmids
designated Luc CCR6 Mut BS1, Luc CCR6 Mut BS2 and
Luc CCR6 Mut BS1 + 2, respectively, as presented in
Figure 4. Mutations were confirmed by DNA sequencing
of the mutated region. Subsequently, the mutated seed
sequences were applied in a luciferase assay with miR-
518a-5p mimics. We have demonstrated that luciferase
activity observed with the Luc CCR6 Mut vectors is
significantly up-regulated with respect to the Luc CCR6
vector in HEK 293 T cells as shown in Figure 5. In this
respect, functional confirmation of the predicted target
site for miR-518a-5p was achieved by site-directed muta-
genesis of the seed sequences in the 3′UTR of CCR6
and subsequent application of the mutated seed sequen-
ces in a luciferase assay with miR-518a-5p mimics.
miR-518a-5p down-regulates CCR6 expression in different
CRC cell lines
Following transfection of CRC cell lines with miR-518a-
5p mimics, monitoring of CCR6 mRNA and protein
expression was performed. For transfection of miRNA
mimics two CRC cell lines with and without metastaticmiR-518a-5p was predicted by target prediction programs TargetScan
3–1779 on the CCR6 3′UTR. Paired sequence alignment is marked by
Figure 2 Dual luciferase reporter assay system with and without
3′UTR of CCR6. The luciferase reporter vectors used in the Dual
Luciferase Reporter assay system contain either a control vector with
no 3′UTR (Luc No CCR6) (A) or a vector with the 3′UTR of CCR6
downstream of the firefly luciferase gene (Luc CCR6) (B). Predicted
alignment sequence of Hsa-miR-518a-5p contains positions 222–228
and 1773–1779 on the 3′UTR of CCR6. Bold labels refer to the
respective seed sequences of miR-518a-5p in the 3′UTR of CCR6.
Figure 3 Luciferase activity in miR transfected 293 T cells.
Luciferase activity in 293 T cells cotransfected with Luc CCR6 and
Luc No CCR6 vectors, respectively, and miR-518a-5p relative to
negative control (NK) miR mimic transfected cells. Luciferase activities
are presented as mean +/− SEM (n = 10). Co-transfection with hsa-miR-
518a-5p resulted in significant down-regulation of luciferase activity
*(P < 0.05) with respect to Luc No CCR6 and NK miR mimic transfected
cells. Fold decrease below 1 indicates luciferase down-regulation in
Luc CCR6/hsa-miR-518a-5p cotransfected tissues related to NK miR
mimic transfected cells.
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Gene expression of CCR6 was monitored after 48 hours
after transfection with miR-518a-5p at the mRNA level
and after 72 hours after transfection with miR-518a-5p
at the protein level using Realtime PCR and immunocyto-
chemistry, respectively. As presented in Figure 6A, CCR6
mRNA expression was significantly down-regulated in
both cell lines under investigation, HT-29 and Caco-2,
respectively (P < 0.05). These results were also reflected in
CCR6 protein expression after immunocytochemical
staining of both cell lines (Figure 6B). In Caco-2 CCR6
mRNA expression was significantly down-regulated by
nearly 70% while in HT-29 CCR6 mRNA expression was
significantly down-regulated by approximately 50%.
Discussion
In this study we investigated functional interactions
between miR-518a-5p and chemokine receptor CCR6.Hereby, we have provided evidence that miR-518a-5p
regulates the expression of a luciferase construct con-
taining the 3′UTR of CCR6. Moreover, we have demon-
strated that in two CRC cell lines, Caco-2 and HT-29,
respectively, artificial miR-518a-5p over-expression by
transfection with miR-518a-5p mimics leads to signi-
ficantly decreased expression of CCR6 both at the mRNA
and protein level. Consequently, it appears that miR-518a-
5p regulates CCR6 expression by a regulatory element
present in the 3′UTR of CCR6. It may be deduced that
miR-518a-5p functionally interacts with the 3′UTR of
CCR6 and down-regulates CCR6 expression in CRC
cell lines.
Functional confirmation of the predicted target site for
miR-518a-5p was achieved by site-directed mutagenesis
of the seed sequences in the 3′UTR of CCR6 and subse-
quent application of the mutated seed sequences in a
luciferase assay with miR-518a-5p mimics. While co-
transfection of HEK cell line 293 T with the Luc CCR6
vector and miR-518a-5p precursors, respectively, resulted
in a significant 60% down-regulation of luciferase activity,
transfection with Luc CCR6 Mut BS2 and Luc CCR6 Mut
BS1 + 2, respectively, totally repressed the inhibitory effect
of miR-518a-5p on luciferase expression and restored
luciferase expression back to 100%. Therefore, mutation
of one of the predicted target site alone and in combin-
ation with the other predicted target site entirely in-
hibit the effect of the miRNA. Therefore, site-directed
mutagenesis of the seed sequences verified the func-
tional interaction of miR-518a-5p with CCR6. In contrast,
transfection with Luc CCR6 Mut BS1 alone did not
entirely repress the inhibitory effect of miR-518a-5p on
luciferase expression. If there is more than one target site
Figure 5 Luciferase activity after site-directed mutagenesis in
miR-518a-5p transfected 293 T cells. Luciferase activity in 293 T
cells cotransfected with Luc CCR6, Luc No CCR6 and Luc CCR6 Mut
BS1, Luc CCR6 Mut BS2 and Luc CCR6 Mut BS1 + 2, respectively, and
miR-518a-5p relative to NK miR mimic transfected cells. Luciferase
activities are presented as mean +/− SEM (n= 10). Luciferase activity
after Site Directed Mutagenesis of the 3′UTR of CCR6 in the miR-518a-5p
Seed Sequences was significantly higher in all three mutated plasmids
with respect to the Luc-CCR6 vector transfected cells *(P < 0.05). Fold
decrease below 1 indicates luciferase down-regulation related to NK miR
mimic transfected cells.
Figure 4 Dual luciferase reporter assay system with mutated
3′UTR of CCR6. Site-directed mutagenesis was introduced into the
2 seed sequences of hsa-miR-518a-5p in positions 222–228 and
1773–1779 in the 3′UTR of CCR6 resulting in three mutated
luciferase expression vectors designated (A) Luc CCR6 Mut BS1,
(B) Luc CCR6 Mut BS2 and (C) Luc CCR6 Mut BS1 + 2, respectively.
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tion of one target site may not be able to entirely inhibit
the effect of the miRNA, whereas mutating both sites
often totally inhibits miRNA mediated expression inhib-
ition [26]. This mechanism may impact the 3′UTR of
CCR6 with respect to miR-518a-5p. However, luciferase
activity observed with the Luc CCR6 Mut BS1 alone was
still demonstrated to be significantly up-regulated withrespect to the intact Luc CCR6 vector without a mutation
in the 3′UTR of CCR6. Comparing luciferase activity
observed with Luc CCR6 Mut BS1 to the luciferase activ-
ity observed with the Luc No CCR6 vector, we did not
observe any significant difference. Although luciferase
activity was not entirely restored after transfection with
the vector carrying only a mutation in the first seed se-
quence, the inhibitory effect of miR-518a-5p on luciferase
expression was still significantly counteracted by the
mutation in the first seed sequence. Therefore, our results
reflect a comprehensible image of the successive counter-
acting effects of the different mutational steps in the 3′
UTR of CCR6 on the luciferase activity after transfection
with the different mutated vectors. Our results also dem-
onstrate that a site-directed mutagenesis spanning 4 bp
introduced into the respective seed sequences is effectu-
ally disrupting the interaction of miR-518a-5p with the 3′
UTR of CCR6. To date, various studies have shown that
mutating 3–5 nucleotides is sufficient to disrupt miRNA/
mRNA interaction [27]. Mutating more nucleotides or
deleting the binding site may achhieve a total repression
of miRNA interaction. Such an effect was delineated for
the interaction of mir-27b with PPAR mRNA [28].
Initially, we also investigated on the basis of alignment
studies if there were other miR-518a-5p binding sites in
the 3′UTR or in the coding DNA sequence of CCR6. In
this respect, we detected several other imperfect comple-
mentarity interactions which may repress the protein
translation to some extent. However, the software pro-
grammes have chosen the seed sequence on the basis of
calculations that consider among other factors the melt-
ing temperature and the 3D model of the molecule thus
being able to predict if binding is on principle sterically
Figure 6 CCR6 mRNA and protein expression in miR 518-5p transfected CRC cells. (A) CCR6 mRNA expression as determined by Q-RT-PCR
in CaCo2- and HT-29 cells 48 hours after transfection with hsa-miR-518a-5p. CCR6 Q-RT-PCR data are presented as mean +/− SEM (n = 15). Fold
decrease below 1 indicates CCR6 mRNA down-regulation in CaCo2- and HT-29 cells relative to NK miR mimic transfected cells, *(P < 0.05). (B) Detection
of CCR6 protein expression in representative cell culture slides of CaCo2- and HT-29 cells as assessed by immunocytochemical staining with CCR6-specific
antibodies.
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mentarity interactions based on our alignment studies,
but the seed sequence calculated by the software tools
may be the only one that sterically fits the 3D model
and therefore allows binding in vivo causing the effect of
downregulation of luciferase activity. This was confirmed
by mutating the seed sequence as described above, which
totally repressed the inhibitory effect of miR-518a-5p on
luciferase expression and restored luciferase expression
back to 100% when transfected with Luc CCR6 Mut BS2
and Luc CCR6 Mut BS1 + 2, respectively. If other im-
perfect binding sites were causing the effect of down-
regulation of luciferase activity, mutation of the seed
sequence alone could not have reversed the effect. In this
way functional confirmation of the predicted target site
for miR-518a-5p was unambigiously shown.Screening for microRNA target sites in the 3′UTR of
CCR6 identified several miRNAs that potentially interact
with the 3′UTR of CCR6. In this context, we have found
three other miRNAs predicted by the target prediction
programmes to bind to the 3′UTR of CCR6. As miR-
518a-5p was predicted by three of the five prediction
programmes, we have started our investigations with this
miRNA. However, at this stage we report a functional
interaction between miR-518a-5p and its identified che-
mokine receptor target CCR6 in CRC cell lines. Further
investigations will show if such functional interactions
are permitted on the cellular level which would require
an inverse correlation of expression and also co-expres-
sion of miR-518a-5p and CCR6 by the same cell. In this
respect, the other three miRNAs predicted by the soft-
ware prediction programmes may also turn out to be
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tions with CCR6.
Following luciferase assays we demonstrated that miR-
518a-5p also down-regulates CCR6 expression in differ-
ent CRC cell lines. For CRC cell lines we have chosen
one cell line with metastatic potential, HT-29, and another
cell line without metastatic potential, Caco-2, respectively.
48 hours after transfection with miR-518a-5p mimics
CCR6 mRNA expression was monitored and shown to be
significantly down-regulated in both cell lines which was
also demonstrated for CCR6 protein expression 72 hours
after transfection with miR-518a-5p mimics by immuno-
cytochemical staining of both cell lines. In this way, we
have shown that independently of the metastatic potential
of a CRC cell line artificial miR-518a-5p over-expression
by transfection of miR-518a-5p mimics leads to signifi-
cantly decreased expression of CCR6 on the mRNA and
protein level. The latter may have been achieved by in-
hibition of translation or mRNA degradation which may
depend on the degree of complementarity between the
microRNA sequence and the target sequence in the 3′
UTR region [1]. High complementarity leads to degrad-
ation of mRNA while lower complementarity leads to
translation repression [14,29].
As we have shown, expression of CCR6 and its corre-
sponding ligand CCL20 is significantly dysregulated in CRC
and colorectal liver metastasis when compared with normal
mucosa [15,16,30]. Consequently, the CCR6/CCL20 system
may be involved in the molecular mechanisms controlling
CRC pathology. In this context, recent data support an
involvement of the CCR6/CCL20 system in CRC pathology.
One study reported that tumor-associated macrophages re-
cruit CCR6+ regulatory T cells to tumor mass and promote
its development via enhancing the production of CCL20 in
a CRC mouse model [31]. Based on a multivariable analysis
another study suggested that preoperative serum carcino-
embryonic antigen level of CCR6 was an independent
factor associated with distant metastasis [32]. Consequently,
it was concluded that the expression of CCR6 in CRC could
predict metachronous distant metastasis.
Recently, we have demonstrated that miR-21 function-
ally interacts with 3′UTR of CCL20 and verified this
interaction in CRC cells [22]. To date, there are no data
investigating putative interactions of the sole CCL20
receptor CCR6 with candidate miRNAs. However, recent
studies allocate a role in CRC pathogenesis to various
miRNAs. MiRNAs are associated with the development
and progression of CRC, partly by regulating the expres-
sion of oncogenes and tumour suppressors and partly by
functioning as oncogenes or tumour suppressors them-
selves [33,34] Accordingly, in CRC the expression of
various miRNAs has been demonstrated to be aberrantly
expressed, mainly down-regulated [20,21]. Artificial dys-
regulation of certain miRNAs will trigger tumorigenesis orapoptosis and will influence CRC prognosis. As a result,
overexpression of miR-21 is associated with worse progno-
sis and poorer response to chemotherapeutics in CRC.
Recently, miR-21 was demonstrated to post-transcription-
ally down-regulate tumor suppressor Pdcd4 and over-
expression of miR-21 stimulated tumor cells to invade,
intravasate and metastasise more aggressively when im-
planted into CRC mouse models [35]. Little is known for
miR-518a-5p with respect to a role in cancer. To date,
miR-518a-5p is speculated as a putative candidate for an
involvement in the development of cervical carcinoma as
it was found to be differentially regulated in high-grade
CIN specimens and cervical squamous cell carcinoma
with respect to normal cervical epithelium [36].
Increasing evidence indicates that the global transcrip-
tional down-regulation of miRNAs in CRC is caused by
epigenetic processes [37]. In this respect, miR-137 and
miR-342 both act as tumour suppressors and are frequen-
tly silenced by promoter hypermethylation in early stages
of CRC [37,38]. In addition, miR-137 was shown to target
cdc42 expression, inducing cell cycle g1 arrest and inhibit-
ing invasion in CRC cells [39]. Also miR-185 was shown
to target cdc42 and RhoA expression thus inhibiting the
proliferation potential of CRC cells [40] while miR-135
affects the Wnt signalling pathway by downregulating the
tumour suppressor gene Adenomatous Polyposis Coli
(APC) [41]. Another potential tumour-suppressive miRNA
in CRC development is miR-143, which might regulate
DNA methylation by targeting DNA methyltransferase 3A
(DNMT3A) [42]. Although the role of miRNAs in the
development of CRC metastasis has been investigated
using in vitro assays, mouse models and tissue-based ex-
periments in CRC patients, the amount of data is still
limited. However, cells with a permanent inactivation of
tumour suppressive factors have a selective advantage to
metastasize. Hence, miR-34a, a member of the miR-34
family (consisting of miR-34a, miR-34b, and miR-34c) was
identified as a direct downstream transcriptional target of
the multifunctional tumour suppressor gene TP53 [43].
Many miR-34a-responsive genes regulate cell cycle pro-
gression, cellular proliferation (E2F) or apoptosis (BCL2).
Therefore, transfection of CRC cells with miR-34a induces
senescence and apoptotic cell death [43,44]. However, if
CRC cells show the presence of TP53 mutations [45] a
significant number of primary tumours demonstrate
decreased miR-34a expression [44]. and therefore have
a higher ability to metastasize. Alternatively, epigenetic
inactivation of the miR-34 family by promoter hyperme-
thylation is observed in many CRC cell lines [46,47] and
primary CRCs [48,49].
Based on previous results that demonstrated aberrant
expression of chemokine receptor CCR6 in CRC tissues,
we hypothesized that CCR6 may be aberrantly regulated
by miRNAs in CRC. To test this hypothesis, we aimed
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CRC cells. In summary, our results indicate a direct
functional interaction of miR-518a-5p with the chemo-
kine target gene CCR6 in CRC cells. Further, we have
demonstrated that miR-518a-5p down-regulates CCR6
expression in miR-518a-5p transfected CRC cell lines.
Hence, we have shown that miR-518a-5p regulates
CCR6 expression in CRC cells which may be a general
regulatory mechanism involved in the development and
progression of CRC.Conclusions
In conclusion, our results provide evidence that miR-
518a-5p functionally interacts with the 3′UTR of CCR6. It
is further documented that transfection of CRC cells with
miR-518a-5p leads to significant CCR6 down-regulation
on the mRNA and protein level. Consequently, our find-
ings may aid in the understanding of miRNA gene regula-
tion with respect to chemokines and their interaction in
CRC cells emphasizing the importance of further studies
of the regulative mechanism underlying the miR-518a-5p/
CCR6 interaction.
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